Assessing the introduction of universal rotavirus vaccination in the Netherlands

T. P. Zomer; Y. T. H. P. van Duynhoven; M. J. J. Mangen; N. A. T. van der Maas; H. Vennema; H. Boot; H. E. de Melker

doi:10.1016/j.vaccine.2008.04.039

Assessing the introduction of universal rotavirus vaccination in the Netherlands

T. P. Zomer, Y. T. H. P. van Duynhoven, M. J. J. Mangen, N. A. T. van der Maas, H. Vennema, H. Boot, H. E. de Melker^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	3757-3764
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	29-30
DOIs	https://doi.org/10.1016/j.vaccine.2008.04.039
Publication status	Published - 4 Jul 2008

Keywords

rotavirus vaccination
gastroenteritis
National Immunization Program
cost-effectiveness
GROUP-A ROTAVIRUS
RISK-FACTORS
UNITED-STATES
VIRAL GASTROENTERITIS
CEREBROSPINAL-FLUID
MALAWIAN CHILDREN
HEALTHY INFANTS
INFECTION
SAFETY
EFFICACY

Access to Document

10.1016/j.vaccine.2008.04.039

Cite this

@article{f95376ec36b94545a221e2957933427f,

title = "Assessing the introduction of universal rotavirus vaccination in the Netherlands",

abstract = "Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.",

keywords = "rotavirus vaccination, gastroenteritis, National Immunization Program, cost-effectiveness, GROUP-A ROTAVIRUS, RISK-FACTORS, UNITED-STATES, VIRAL GASTROENTERITIS, CEREBROSPINAL-FLUID, MALAWIAN CHILDREN, HEALTHY INFANTS, INFECTION, SAFETY, EFFICACY",

author = "Zomer, {T. P.} and {van Duynhoven}, {Y. T. H. P.} and Mangen, {M. J. J.} and {van der Maas}, {N. A. T.} and H. Vennema and H. Boot and {de Melker}, {H. E.}",

year = "2008",

month = jul,

day = "4",

doi = "10.1016/j.vaccine.2008.04.039",

language = "English",

volume = "26",

pages = "3757--3764",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "29-30",

}

TY - JOUR

T1 - Assessing the introduction of universal rotavirus vaccination in the Netherlands

AU - Zomer, T. P.

AU - van Duynhoven, Y. T. H. P.

AU - Mangen, M. J. J.

AU - van der Maas, N. A. T.

AU - Vennema, H.

AU - Boot, H.

AU - de Melker, H. E.

PY - 2008/7/4

Y1 - 2008/7/4

N2 - Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

AB - Rotarix and RotaTeq are both prophylactic vaccines against rotavirus (RV) gastroenteritis. In 2006, these vaccines obtained a European license and because RV infections are widespread among Dutch children inclusion of these vaccines in the Dutch National Immunization Program(NIP) should be considered. Using an evaluation model for introducing a new vaccine, we assessed the introduction of universal RV vaccination in the Netherlands. Although post-marketing surveillance will be essential, both RV vaccines have proven to be safe and effective. Furthermore, the vaccines will prevent most of the RV-related hospitalizations and deaths. However, for the Netherlands with the current vaccine prices, universal RV vaccination is not expected to be cost-effective. (C) 2008 Elsevier Ltd. All rights reserved.

KW - rotavirus vaccination

KW - gastroenteritis

KW - National Immunization Program

KW - cost-effectiveness

KW - GROUP-A ROTAVIRUS

KW - RISK-FACTORS

KW - UNITED-STATES

KW - VIRAL GASTROENTERITIS

KW - CEREBROSPINAL-FLUID

KW - MALAWIAN CHILDREN

KW - HEALTHY INFANTS

KW - INFECTION

KW - SAFETY

KW - EFFICACY

U2 - 10.1016/j.vaccine.2008.04.039

DO - 10.1016/j.vaccine.2008.04.039

M3 - Article

C2 - 18514975

SN - 0264-410X

VL - 26

SP - 3757

EP - 3764

JO - Vaccine

JF - Vaccine

IS - 29-30

ER -

Assessing the introduction of universal rotavirus vaccination in the Netherlands

Abstract

Keywords

Access to Document

Fingerprint

Cite this